Tags

Type your tag names separated by a space and hit enter

Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.
J Infect Public Health. 2022 Feb; 15(2):277-288.JI

Abstract

The heterogeneous phenotypes among patients with coronavirus disease 2019 (COVID-19) has drawn worldwide attention, especially those with severe symptoms without comorbid conditions. Immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative virus of COVID-19, occur mainly by the innate immune response via the interferon (IFN)-mediated pathways, and the adaptive immunity via the T lymphocyte and the antibody mediated pathways. The ability of the original Wuhan SARS-CoV-2 strain, and possibly more so with new emerging variants, to antagonize IFN-mediated antiviral responses can be behind the higher early viral load, higher transmissibility, and milder symptoms compared to SARS-CoV and are part of the continued clinical evolution of COVID-19. Since it first emerged, several variants of SARS-CoV-2 have been circulating worldwide. Variants that have the potential to elude natural or vaccine-mediated immunity are variants of concern. This review focuses on the main host factors that may explain the immune responses to SARS-CoV-2 and its variants in the context of susceptibility, severity, and preexisting immunity.

Links

PMC Free PDF

Authors+Show Affiliations

Alefishat E
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
Jelinek HF
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Center of Heath Engineering Innovation, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Mousa M
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Nuffield Department of Women's and Reproduction Health, Oxford University, Oxford, United Kingdom.
Tay GK
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Discipline of Psychiatry, Medical School, the University of Western Australia, Perth WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Alsafar HS
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Genetics and Molecular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Emirates Bio-Research Center, Ministry of Interior, Abu Dhabi, United Arab Emirates. Electronic address: habiba.alsafar@ku.ac.ae.

MeSH

COVID-19COVID-19 VaccinesHumansImmunitySARS-CoV-2

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

35074728

Citation

Alefishat, Eman, et al. "Immune Response to SARS-CoV-2 Variants: a Focus On Severity, Susceptibility, and Preexisting Immunity." Journal of Infection and Public Health, vol. 15, no. 2, 2022, pp. 277-288.
Alefishat E, Jelinek HF, Mousa M, et al. Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. J Infect Public Health. 2022;15(2):277-288.
Alefishat, E., Jelinek, H. F., Mousa, M., Tay, G. K., & Alsafar, H. S. (2022). Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. Journal of Infection and Public Health, 15(2), 277-288. https://doi.org/10.1016/j.jiph.2022.01.007
Alefishat E, et al. Immune Response to SARS-CoV-2 Variants: a Focus On Severity, Susceptibility, and Preexisting Immunity. J Infect Public Health. 2022;15(2):277-288. PubMed PMID: 35074728.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. AU - Alefishat,Eman, AU - Jelinek,Herbert F, AU - Mousa,Mira, AU - Tay,Guan K, AU - Alsafar,Habiba S, Y1 - 2022/01/13/ PY - 2021/9/14/received PY - 2021/11/16/revised PY - 2022/1/9/accepted PY - 2022/1/26/pubmed PY - 2022/2/9/medline PY - 2022/1/25/entrez KW - Antibody-dependent enhancement (ADE) KW - COVID-19 KW - Cross-reactivity KW - SARS-CoV-2 KW - Severity KW - Variants of concern SP - 277 EP - 288 JF - Journal of infection and public health JO - J Infect Public Health VL - 15 IS - 2 N2 - The heterogeneous phenotypes among patients with coronavirus disease 2019 (COVID-19) has drawn worldwide attention, especially those with severe symptoms without comorbid conditions. Immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative virus of COVID-19, occur mainly by the innate immune response via the interferon (IFN)-mediated pathways, and the adaptive immunity via the T lymphocyte and the antibody mediated pathways. The ability of the original Wuhan SARS-CoV-2 strain, and possibly more so with new emerging variants, to antagonize IFN-mediated antiviral responses can be behind the higher early viral load, higher transmissibility, and milder symptoms compared to SARS-CoV and are part of the continued clinical evolution of COVID-19. Since it first emerged, several variants of SARS-CoV-2 have been circulating worldwide. Variants that have the potential to elude natural or vaccine-mediated immunity are variants of concern. This review focuses on the main host factors that may explain the immune responses to SARS-CoV-2 and its variants in the context of susceptibility, severity, and preexisting immunity. SN - 1876-035X UR - https://www.unboundmedicine.com/medline/citation/35074728/Immune_response_to_SARS_CoV_2_variants:_A_focus_on_severity_susceptibility_and_preexisting_immunity_ DB - PRIME DP - Unbound Medicine ER -